Leiomyosarcomas of the vascular system (vLMSs) are rare tumors that commonly originate from large proximal and central veins. Pancreatic metastasis is rare for sarcomas, and surgical excision with large margins is the treatment of choice. We present a case of a 32-year-old female with primary vLMS originating from the distal crural veins and local invasion of the fibula. A prior open biopsy site was suboptimal. The patient was treated with neoadjuvant chemotherapy and radiotherapy, followed by surgery. The follow-up radiological imaging showed pancreatic head metastasis, which is also an extremely rare site for vLMS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931263 | PMC |
| http://dx.doi.org/10.7759/cureus.13073 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk Stratification of Uterine Smooth Muscle Tumors: The Role of Morphology, Immunohistochemistry, and Molecular Testing.
Adv Anat Pathol
January 2025
Department of Pathology, University of Michigan-Michigan Medicine, Ann Arbor, MI.
Uterine smooth muscle neoplasms are a biologically and clinically heterogeneous group of tumors. Morphology is the cornerstone of pathologic diagnosis of these tumors, and most are readily classified as benign or malignant on the basis of routine histologic examination. However, rare subsets-including intravenous leiomyomatosis, benign metastasizing leiomyoma, and disseminated peritoneal leiomyomatosis-have a capacity for extrauterine spread despite benign cytomorphology.
View Article and Find Full Text PDFThe Fatty Dilemma: A Rare Instance of Extra- and Intravascular Lipoma of the Brachiocephalic Vein.
Indian J Radiol Imaging
January 2025
Department of Radiodiagnosis, Continental Hospitals, Hyderabad, Telangana, India.
Oftentimes, incidental findings are made on routine diagnostic imaging. An intra- and extravascular lipoma is one example of an important incidental finding. Intravascular lipomas are rare benign vascular tumors that are typically asymptomatic.
View Article and Find Full Text PDFPrimary hepatic leiomyosarcoma masquerading as liver abscess: A case report.
World J Gastrointest Surg
November 2024
Department of Hepatobiliary and Pancreatic Surgery, Lishui Municipal Central Hospital, Lishui 323000, Zhejiang Province, China.
Background: Primary hepatic leiomyosarcoma (PHL) is a rare malignant tumor and has non-specific clinical manifestations and imaging characteristics, making preoperative diagnosis challenging. Here, we report a case of PHL presenting primarily with fever, with computed tomography imaging showing a thick-walled hepatic lesion with low-density areas, resembling liver abscess.
Case Summary: The patient was a 34-year-old woman who presented with right upper abdominal pain and fever over 4 days before admission.
Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies.
BMC Cancer
December 2024
Department of Clinical Therapeutics, Medical School, Alexandra Hospital, 11528, Athens, Greece.
Article Synopsis
- HER2 overexpression is a significant target for treating gynecological cancers, and Trastuzumab-Deruxtecan (T-DXd) has shown notable effectiveness against these cancers, particularly in ovarian, endometrial, and cervical malignancies.
- A study was conducted at the Alexandra Hospital in Athens involving 10 patients with HER2-positive gynecological cancers who were treated with T-DXd, administered intravenously every 3 weeks.
- Results indicated a median progression-free survival of 5.4 months, with 5 patients achieving a partial response, highlighting T-DXd's potential as a treatment option even for patients with prior therapies.
Real-World Outcomes of Patients Treated With Gemcitabine Using Standardized Dose and Rate and Docetaxel for Advanced Soft Tissue Sarcoma in an Australian Sarcoma Center.
Asia Pac J Clin Oncol
November 2024
Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Background: Gemcitabine and docetaxel (GD) is a common chemotherapy regimen for metastatic soft tissue sarcoma (STS). The GeDDiS trial compared GD with doxorubicin in the first-line setting, using gemcitabine 675 mg/m over a prolonged rate of 90 min-reporting a 20% response rate and 5.4-month median progression-free survival (PFS).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!